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Abstract
The aim of the present study was to investigate the associations between the habitual Ca intake and faecal fat and energy excretion as well as blood lipid
proﬁle in free-living normal-weight and overweight individuals. The participants were enrolled for an 8-d period where data from a 7-d diet registration
(days 1–7), a 5-d faeces collection (days 3–7), a 2-d urine collection (days 5–7), and anthropometric measurements and a fasting blood sample (day 8) were
collected. Analyses showed that dietary Ca intake (g/10 MJ per d) was positively associated with excretion of faecal fat (P= 0·004) and energy (P = 0·031)
when adjusted for BMI, age, sex and intake of Ca-containing supplements. However, after adjustment for intake of ﬁbre, the effect of Ca intake disap-
peared. Nevertheless, total cholesterol (CHOL) and LDL-CHOL concentrations were associated negatively with Ca intake (β −0·62 (95 % CI −0·96,
−0·28) mmol/l, P< 0·001, and β −0·49 (95 % CI −0·78, −0·20) mmol/l, P= 0·001, respectively, per 1000 mg/10 MJ per d increase in Ca intake).
In conclusion, incorporation of Ca-rich food products in a habitual diet was associated with reduced total CHOL and LDL-CHOL concentrations,
which may lower the risk of CVD in the long term.
Key words: Dietary calcium: Faecal fat excretion: Faecal energy excretion: Lipid proﬁle: Cholesterol
More than 1·9 billion adults are overweight or obese world-
wide(1) and obesity is considered a global health issue because
it increases the risk of CVD and diabetes(1). Weight-loss (main-
tenance) diets have been intensively investigated, especially with
focus on the energy-providing macronutrients(2–5). However, the
micronutrient Ca has been associated with reduced BMI since
1984(6). Subsequently, many studies have found negative associa-
tions of dairy product or Ca intakes with anthropometric mea-
surements(6–23). Additionally, a higher Ca intake has been
associated with reduced insulin concentration(15), blood pressure
(BP)(6,14,18) and reduced risk of the metabolic syndrome(18,24,25)
as well as an improved blood lipid proﬁle(7,18). Nonetheless, the
negative anthropometric association with Ca has not been con-
sistently shown(26–30), and the effect of a higher Ca intake on
body weight has not been clearly proven by randomised
controlled trials (RCT) or meta-analyses(31–35).
One of several theories is that Ca binds fat in the intestine,
especially the long-chain fatty acids, which causes the forma-
tion of insoluble Ca–fatty acid soaps(36,37). The decreased solu-
bility of fatty acids and monoacylglycerols in the micelles
lowers cholesterol (CHOL) solubility and causes the formation
of large aggregates that are unlikely to be absorbed(38). Thus, a
higher Ca intake will result in increased faecal fat excretion(39).
Additionally, Ca precipitates bile acids(40), which reduces the
enterohepatic recycling of bile acids and causes de novo synthe-
sis of bile acids from blood CHOL. Overall, this may lead to
an improved blood lipid proﬁle.
In observational studies, intakes of dairy products and Ca
have been associated with dyslipidaemia(24), total CHOL(7,28),
LDL-CHOL(7), HDL-CHOL(18), total CHOL:HDL-CHOL
ratio(7) and TAG(24). However, the ﬁndings are not consistent.
Some studies have found reduced total CHOL and
Abbreviations: BP, blood pressure; CHOL, cholesterol; Q1, ﬁrst quartile; Q3, third quartile; RCT, randomised controlled trial.
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LDL-CHOL concentrations or increased HDL-CHOL concen-
tration associated with reduced risk of CVD(41–45), but others
observed that the total CHOL:HDL-CHOL or LDL-CHOL:
HDL-CHOL ratio(42,46,47) was a better predictor for CVD
than the isolated blood lipid concentrations. In intervention
studies, increased Ca intake from fortiﬁed products(48,49), diet-
ary supplements(17,50–53), milk(34,54,55), cheese(55–57), yog-
hurt(14) and a mixture of dairy products(15,17,35,50,58–60), as
well as Ca intake combined with different fat(61) or protein(60)
contents, have been investigated. Still, the exact quantity of
faecal fat excretion and effect on the lipid proﬁle in relation
to the increased Ca intake is inconsistent.
A frequently raised concern is whether the short-term effect
of Ca observed in intervention studies will decrease over time
due to adaptation to a long-term high habitual Ca intake.
Therefore, the aim of the present study was to investigate
the association between habitual Ca intake and faecal fat and
energy excretion in free-living normal-weight and overweight
persons as well as the association between habitual Ca intake
and blood lipid proﬁle.
Participants and methods
Study design
The study included participants from two trials with similar
design for the baseline measurements. In both trials, data
were obtained during an 8-d period. The participants’ dietary
intake was assessed by a 7-d dietary registration where the par-
ticipants weighed all foods (days 1–7). Participants recorded
physical activity, smoking habits, intake of medication and ill-
ness on days 1–7 and women recorded their menstrual cycle.
Faecal samples were collected in pre-weighed plastic contain-
ers over 5 d (days 3–7) and complete 48-h urine collection
was carried out (days 6–7). On day 8, anthropometric mea-
surements and BP measurements were performed and a fast-
ing (12 h) blood sample was drawn at the Department.
Trial I (clinical trial no. NCT01542164; https://clinicaltrials.
gov) was an observational study carried out from June 2009 to
March 2011. The primary aim was to investigate the associa-
tions between habitual Ca intake and faecal fat and energy
excretion as well as the association between habitual Ca intake
and lipid proﬁle. Individuals were recruited with the goal to
obtain forty participants in each of the four groups: (A)
BMI > 25 kg/m2 and habitual dietary Ca intake ≤800 mg/d;
(B) BMI > 25 kg/m2 and habitual dietary Ca intake >800
mg/d; (C) BMI≤ 25 kg/m2 and habitual dietary Ca intake
≤800 mg/d; (D) BMI≤ 25 kg/m2 and habitual dietary Ca
intake ≤800 mg/d. At inclusion, BMI was calculated from
self-reported weight and height and habitual Ca intake was
assessed by a self-administered quantitative FFQ highly similar
to a FFQ previously validated(62). Trial II (clinical trial no.
NCT01199835; https://clinicaltrials.gov) was an intervention
study with a randomised parallel design. Overweight and
obese participants (BMI 28–33 kg/m2) were randomised to
a 24-week intake of a hypoenergetic diet with either a high
or a low intake of dairy products. A minimum of forty (and
up to ﬁfty) participants were recruited for each group. It was
carried out from June 2010 to August 2011 and the aim was
to investigate the effect of the hypoenergetic high- v. low-dairy
diets on weight loss and faecal excretion of fat and energy.
Furthermore, the effects on BP, blood lipid proﬁle, lipid oxi-
dation and appetite regulation were investigated (described
elsewhere; Bendtsen et al.(63)).
Both studies were conducted according to the guidelines laid
down in the Declaration of Helsinki and all procedures involving
human participants were approved by the responsible regional
committee on human experimentation in Denmark
(H-B-2009-071 (trial I) and H-3-2010-049 (trial II)).
Furthermore, the studies were registered in Clinical Trial and
the Danish Data Protection Agency (both studies:
2007-54-0269). Written informed consent was obtained from
all participants and both studies were carried out at the
Department of Nutrition, Exercise and Sports, Faculty of
Science, University of Copenhagen, Denmark.
Participants
Individuals were recruited through advertisements posted on a
university web page (forsøgsperson.dk) and in the local/free
newspaper. Potential individuals were pre-screened by tele-
phone in accordance with the inclusion and exclusion criteria
and those who fulﬁlled the criteria were sent written informa-
tion and the FFQ. Finally, those who fulﬁlled BMI and habit-
ual Ca criteria were invited to an information meeting where
the informed consent was signed.
The inclusion criteria in trial I were 18–50 years and weight
stable (±4 kg 4 months prior to study start), and in trial II par-
ticipants were 18–60 years and had a habitual low Ca intake
(<800 mg/d) evaluated by the FFQ. In both studies, indivi-
duals were excluded if they were pregnant or lactating, used
CHOL-decreasing medication or other types of medication
assessed to inﬂuence the study outcomes. Furthermore, diet-
ing individuals or individuals with a temporary change in diet-
ary habits as well as individuals with previous and present
gastrointestinal diseases were excluded. In trial II individuals
with milk allergy, infectious disease and metabolic diseases
were excluded too. Smokers and individuals who had taken
dietary supplements 6 months prior to (and during the study)
were excluded in trial II, whereas in trial I participants recorded
their smoking habits and intake of dietary supplements. In trial
I, individuals with physical activity more than 8 h/week were
excluded. In general, the participants were not allowed to par-
ticipate in other studies in parallel. However, data collected in
trial I constituted the majority of the baseline measurements
in trial II; therefore participants were allowed to participate in
these two studies at the same time.
As compensation, participants received 1000 Danish
Crowns (about US$185) after completion of trial I. The
same compensation was provided in trial II, but only if the
participant completed a sub-study.
Outcomes
The primary outcomes were faecal fat and energy excretion.
Secondary outcomes were fasting blood lipid proﬁle (total
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CHOL, LDL-CHOL, HDL-CHOL, NEFA and TAG), rest-
ing BP as well as the faecal and urinary excretion of Ca.
Data collection
In both trials, data were obtained during an 8-d period. In trial
I, data were obtained once. In trial II (the RCT), only baseline
data were used for analyses.
Anthropometry and blood pressure. All participants voided
before anthropometric measurements were performed. Body
weight (in kg with two decimals) was measured by a digital
scale (Lindells). Height was measured twice with 0·5 cm
accuracy using a wall-mounted stadiometer (Hultafors) and the
average of the two measurements was recorded. BMI was
calculated as weight (kg) divided by height squared (m2). After
10 min rest, BP was measured by an automatically inﬂated
cuff (Saitama). BP was measured on both arms and the
subsequent measurements were performed on the arm with
the highest systolic BP. If the subsequent two measurements
differed by more than 5 mmHg, additional measurements
were performed until two consecutive measurements
differed by ≤5 mmHg and an average was recorded.
Dietary records. Weighed 7-d diet records were used to
evaluate habitual Ca intake with the assumption that it would
reﬂect a long-term Ca intake. The participants’ dietary intakes
of energy, macronutrients and micronutrients were calculated
as a daily average from the 7-d diet records. Participants
registered all foods and supplied information on brand names,
cooking and processing. Whenever possible, foods were
weighed; otherwise, household measures were applied. The
dietary registrations were assessed by the computer database
of foods from the National Food Agency of Denmark
(Dankost 3000; National Food Agency of Denmark).
Faeces. Before analysis, faeces samples were weighed,
homogenised and freeze-dried, and all samples from the 5-d
collection period were pooled. Faecal energy was measured
in duplicate by a bomb calorimeter (IKA Calorimeter System
C4000) and the average was recorded. Faecal samples were
hydrolysed with 3 M-HCl and thereafter fat excretion was
measured by the acidic Bligh & Dyer extraction(64). Before
analysis of faecal Ca content, samples were dried at 525°C
for 6 h, ashes were dissolved in 6·5 % HNO3 and the
solution was diluted with a lanthanum chloride solution. To
determine Ca content, samples were measured by atomic
absorption spectrophotometry using a PYE UNICAM SP9
atomic absorption spectrophotometer (Philips Electron Optics).
Urine. During urine collection, participants ingested tablets
of 80 mg para-aminobenzoic acid three times per d (240
mg/d). Before analysis, weight and density of the collected
urine were measured to calculate the volume. Excretion of
urinary Ca was measured using photometric analysis (ABX
Pentra 400 analyser; HORIBA ABX S.A.S.) and urinary N
using the modiﬁed Dumas method with a VarioMax CN
analyser (Elementar).
Blood samples. Fasting blood samples for the analysis of
serum lipids (total CHOL, LDL-CHOL, HDL-CHOL and
TAG) were collected in serum tubes and kept at room
temperature for 30 min to coagulate. Blood samples for
plasma analysis of NEFA were collected in EDTA-containing
tubes and immediately placed on ice. All samples were
centrifuged at 2500 g for 10 min at 4°C and stored at −80°C.
Total CHOL and TAG were measured by enzymic
photometric tests, and HDL-CHOL, LDL-CHOL and
NEFA by enzymic colorimetric tests using a Pentra 400
Analyser (HORIBA ABX). For total CHOL, intra-assay CV
was 1·0 %, whereas inter-assay CV was 1·7 %. For
HDL-CHOL, intra-assay CV was 1·2 %, whereas inter-assay
CV was 5·6 %. For LDL-CHOL, intra-assay CV was 2·4 %,
whereas inter-assay CV was 3·7 %. For NEFA, intra-assay
CV was 1·7 %, whereas inter-assay CV was 5·1 %. For TAG,
intra-assay CV was 3·0 %, whereas inter-assay CV was 3·8 %.
Statistical analyses
Before initiation of trial I, a power calculation was performed
using data from other studies. The mean for Ca intake in
Denmark was assumed to be 967 (SD 394) mg/d(65) and the
standard deviation for the faecal fat excretion was assumed
to be 2 g/d(53). Based on the standard deviation for fat excre-
tion a study with 160 included participants would have a
power of 85 % (accounting for a dropout rate of 10 %) to
detect an association between Ca intake and faecal fat excretion
if the faecal fat excretion increased 1 g/d per 1000 mg/d
increase in Ca intake. Later, a meta-analysis(39) found that an
increase of 800–6000 mg Ca per d increased the faecal fat excre-
tion by a standardised mean difference of 0·99 (95 % CI 0·63,
1·34), corresponding to about 2 g/d.
All statistical analyses were performed using STATA (ver-
sion 10.1). The level of signiﬁcance was set at P< 0·05.
The collected data were examined for means, ranges and
outliers. Normally distributed data are presented as means
and standard deviations, and non-normally distributed data
by medians, and ﬁrst and third quartiles (Q1 and Q3).
Categorical data are presented by the number of participants
in the group. Associations between two parameters (measure-
ments of Ca, fat and energy) were examined by linear regres-
sion. Adjusted R2 was used to assess how well the linear
regression model predicted the dependent variable. All models
were visually inspected by plot of residuals and occasionally
the dependent variable was transformed to obtain normality
of residuals. Cook’s distance was used to identify observations
that deviated from the main population; however, none of the
observations had a Cook’s distance value ≥1.
To analyse the association between dietary Ca intake (g/d)
and the dependent variable faecal fat excretion (g/d) a general
multiple linear regression (model I) was built containing the cov-
ariates of BMI, age, sex and intake of Ca-containing supple-
ments (yes/no). Afterwards, this model was further adjusted
3
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for energy and fat intakes; thus Ca intake was given as g/10 MJ
per d and faecal fat excretion as a percentage of the fat intake
(model II). Further, adjustments for ﬁbre intake and the inter-
action ﬁbre × Ca (model III) were tested because increased
ﬁbre intake(66) and possibly also an interaction between ﬁbre
and Ca(67) have been linked to increased faecal fat excretion.
To analyse the association between dietary Ca intake and the
dependent variable faecal energy excretion (or blood lipid con-
centration (mmol/l or μmol/l) or BP (mmHg)) a general mul-
tiple linear regression (model I) with covariates as described
above was built. This model was further adjusted for energy
intake; thus Ca intake was given as g/10 MJ per d (for inves-
tigation of faecal energy excretion this variable was given as a
percentage of total energy intake). Further adjustments for
ﬁbre and the interaction ﬁbre × Ca (model III) were per-
formed as described above.
The possibility that faecal excretion of fat or energy could
mediate Ca’s association with blood lipid proﬁle was tested
by a mediation analysis described by MacKinnon et al.(68).
Results
In total, 189 participants (129 women and sixty men; Table 1)
were included in the ﬁnal data analysis (Fig. 1). Description of
faecal and urine samples is found in Table 2.
The median faecal and urinary Ca excretion (Table 2) corre-
sponded to a 98 (SD 31) % excretion of the estimated dietary
Ca intake. There was a positive association between dietary
Ca intake and total Ca excretion (β 0·72 (95 % CI 0·59,
0·86), P < 0·001, R2 0·39), and positive associations between
faecal excretion of Ca and fat (β 0·32 (95 % CI 0·26, 0·38),
P < 0·001, R2 0·37) and between faecal excretion of Ca and
energy (β 10·8 (95 % CI 9·19, 12·5), P < 0·001, R2 0·48)
(Supplementary Fig. S1).
Dietary Ca intake (g/d) was associated with faecal fat excre-
tion (β 0·20 (95 % CI 0·12, 0·29); P< 0·001). For each 1000
mg/d increase in Ca intake, faecal fat excretion was predicted
to increase by 59 (95 % CI 31, 94) %, which means that faecal
fat excretion may increase from, for example, 5·7 g/d (Q1) to
9·0 g/d. After adjustment for fat and energy intakes a 1000
mg/10 MJ per d increase in Ca intake was predicted to yield
a 31 % higher fat percentage excretion (P = 0·004) (Table 3).
For example, a 6·6 % excretion of the total dietary fat intake
(Q1) would increase to 8·7 %.
Dietary Ca intake (g/d) was associated with energy excretion
(β 5·74 (95 % CI 3·26, 8·22); P< 0·001). For a woman with
a dietary Ca intake of 856 mg/d (Q1) (median age and BMI,
without consumption of Ca supplements), a 1000 mg/d
increase in Ca intake was related to an increase in faecal energy
excretion of 344 (95 % CI 174, 548) kJ/d. After adjust-
ment for energy intake, the predicted effect on faecal energy
excretion was reduced (P= 0·031) (Table 4). As exempliﬁed
above, a 1000 mg/10 MJ per d increase in Ca intake
would yield a predicted increase in the energy excretion from
8·3 to 9·7 %, which corresponds to a 133 kJ/d increase for a
woman consuming an average energy intake of 9264 kJ/d.
Further adjustments for ﬁbre intake showed no ﬁbre × Ca
interaction, either on faecal fat or energy excretion, but adjusting
for ﬁbre intake, which was signiﬁcantly associated with increased
faecal fat and faecal energy excretion, abolished the positive
association between Ca intake and excretion of faecal fat and
energy (Tables 3 and 4). Intake of Ca-containing supplements
was not associated with the outcomes in any of the models.
For the lipid proﬁle, we observed that a 1000 mg/d increase
in Ca intake (g/d) decreased concentrations of total CHOL by
0·47 (95 % CI 0·11, 0·82) mmol/l (P = 0·011), LDL-CHOL
by 0·47 (95 % CI 0·17, 0·77) mmol/l (P = 0·002) and TAG
by 17 (95 % CI 1·6, 30) % (P = 0·032), and reduced the
total CHOL:HDL-CHOL ratio by 10 (95 % CI 1·4, 18) %
(P = 0·025) and LDL-CHOL:HDL-CHOL ratio by 16 (95
% CI 2·9, 27) % (P = 0·018). After adjustment for energy
intake, total CHOL and LDL-CHOL concentrations
decreased by increasing Ca intake (Table 5). Adjustment for
ﬁbre intake had no signiﬁcant inﬂuence on lipid proﬁle
(Table 5). Concentrations of HDL-CHOL, TAG and
Table 1. Description of the study population (n 189)
(Medians with quartile 1 (Q1) and quartile 3 (Q3); mean values and
standard deviations, unless otherwise specified)
Characteristics Median Q1, Q3
Age (years) 31 24, 44
Anthropometry
Height (m)*
Mean 1·72
SD 0·1
Weight (kg)* 76·4 68·5, 88·9
BMI (kg/m2)* 26·3 22·3, 31·0
Blood pressure
Systolic blood pressure (mmHg)* 118 111, 125
Diastolic blood pressure (mmHg)*
Mean 76·5
SD 10·2
Pulse (beats/min)† 60 55, 65
Lipid profile
Total cholesterol (mmol/l)‡
Mean 4·80
SD 1·04
HDL cholesterol (mmol/l)‡ 1·38 1·14, 1·60
LDL cholesterol (mmol/l)* 2·66 2·13, 3·29
TAG (mmol/l)‡ 0·92 0·65, 1·33
NEFA (μmol/l)* 587 439, 735
Diet
Energy intake (kJ/d) 9744 8392, 11 451
Protein (E%) 15·5 13·9, 17·5
Carbohydrate (E%)
Mean 48·5
SD 5·22
Fat (E%)
Mean 32·0
SD 5·49
SFA (g/d) 29·3 22·2, 36·5
MUFA (g/d) 26·2 21·1, 32·8
PUFA (g/d) 13·0 10·6, 16·3
Dietary cholesterol (mg/d)‡ 308 240, 375
Dietary fibre (g/d) 25·4 20·2, 32·5
Dietary Ca intake (mg/d)§ 1065 856, 1330
FFQ: Ca ≤800 mg/d (%)∥¶ 50·8
E%, energy percentage.
* n 187.
† n 161.
‡ n 188.
§ Habitual Ca intake assessed by a 7-d diet record (without supplements).
∥Value given as a percentage.
¶ Habitual Ca intake assessed by FFQ.
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NEFA, and the total CHOL:HDL-CHOL and LDL-CHOL:
HDL-CHOL ratios were not inﬂuenced by Ca intake when
adjusted for energy intake or by further adjustment for ﬁbre
intake (Supplementary Table S1). Mediation analysis showed
that faecal excretion of fat or energy did not mediate the effect
of Ca intake on lipid proﬁle (Supplementary Table S2).
Ca intake did not inﬂuence systolic BP (P= 0·11) or dia-
stolic BP (P = 0·25). However, when the models were energy
adjusted, systolic BP decreased 5·2 (95 % CI 1·8, 8·4) % per
1000 mg/10 MJ per d increase in Ca intake (P = 0·003).
Discussion
We observed that a higher Ca intake was associated with a
more beneﬁcial lipid proﬁle, i.e. decreased concentrations of
total CHOL and LDL-CHOL as well as a lower systolic BP.
Although a higher Ca intake was associated with higher faecal
fat and energy excretion in the models adjusted for energy,
BMI, age, sex and intake of Ca-containing supplements, the
associations disappeared when adjusted for dietary ﬁbre intake.
Thus, the association with blood lipids did not seem to be
mediated by higher faecal fat or energy excretion.
A meta-analysis of ﬁfteen RCT found that a daily 800–6000
mg higher Ca intake increased the faecal fat excretion by 2 g/d,
corresponding to a 37 % increase(39). There was no difference
in the effect between studies using dairy products v. Ca
supplements; however, the heterogeneity of the overall analysis
(I2 = 49·5 %) suggests possible confounding factors. In our
analysis, a daily 1000 mg/10 MJ higher Ca intake was asso-
ciated with a 31 % increase in fat excretion. However, this
association disappeared when the models were adjusted for
ﬁbre intake (a possible confounder) and it is questionable
how well the effect of ﬁbre intake is considered in the RCT
included in the meta-analysis.
Fig. 1. Flow chart. A total of 158 and ninety-six participants were recruited to trials I and II, respectively. In all, eighteen participants in trial I and fourteen participants
in trial II dropped out before the 8-d data collection period started and one participant in trial I dropped out during the data collection period. Hence, 221 participants
completed the studies. Before data analysis, thirty participants were excluded to avoid repeated measurement from those who participated in both studies and two
participants were excluded due to protocol violation.
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Intervention studies have found that higher Ca intakes from
milk or cheese increase faecal fat excretion from 3·9 to 5·2–
5·7 g/d corresponding to 33–46 % increase per 800 mg/d
Ca(58), from 5·9 to 8·3 g/d corresponding to a 39 % increase
per 1500 mg/d Ca(61) or tend to increase the faecal fat content
from 20 to 23 %(56). The effects in these studies are higher
than in our study but one of the main differences between
these studies and our study is the amount of Ca. These studies
provided very low daily Ca intake in the control groups (362
mg/10 MJ, 417 mg, 504 mg/10 MJ), compared with our study
where the lowest Ca intake was 498 mg/d (557 mg/10 MJ per
d), and only 10 % of our participants had a Ca intake below
661 mg/d (774 mg/10 MJ per d). Another observation is the
low content of dietary ﬁbres in the intervention diets (18·4–
20·3 g/d(58) or 13·5–15·3 g/10 MJ(61)). In our study the ﬁbre
intake was much higher (only 25 % had a ﬁbre intake
<20·2 g and only 10 % an intake <17·1 g/10 MJ) and our ana-
lysis showed that a 10 g/10 MJ per d increase in ﬁbre intake
would increase the faecal fat excretion by 30 %. It can be
speculated, as indicated by other authors(39,49), that a plateau
is reached for the effect of Ca when the Ca intake is as high
as in our study population. Another interesting observation
is the very different amounts of fat excretion in the
RCT(39,58,61). For example, the intake of a milk-based diet
(Ca: 1143 mg/d) in one study resulted in a fat excretion of
5·2 g/d(58), which was very similar to the fat excretion (5·87
g/d) in the control group (Ca: 474–504 mg/10 MJ) of another
study(61). A difference like this is probably related to methods
for the determination of faecal fat content or other dietary fac-
tors that differed between the studies. From our study it is not
clear if the increased fat excretion found in RCT is transient or
if we do not observe the association in our free-living popula-
tion because of the habitual intake of Ca (and ﬁbre) is higher
than that provided in intervention diets.
Several studies have shown that increased Ca intake
increases faecal energy excretion(58–61). The increase in energy
excretion observed in other studies ranges from 96 to 203 kJ/d,
corresponding to a 13–31 % increase by a 800–1600 mg/d
increase in Ca intake(58,59,61), with one study(60) ﬁnding a
361 kJ/d increase (about 53 % increase) by a 1300 mg/d Ca
increase. The former studies are similar to our results showing
an increase of 133 kJ/d per 1000 mg Ca/10 MJ. However,
when adjusting for ﬁbre intake the signiﬁcant association of
Ca disappeared in our study.
Similar to our results, Jacqmain et al.(7) investigated data
from 470 persons in the Québec Family Study and found
that a higher Ca intake was correlated with a reduced ratio
of total CHOL:HDL-CHOL. The ratio of total CHOL:
HDL-CHOL for women was signiﬁcantly reduced by 11·3 %
(from 4·16 to 3·69) when the <600 mg/d Ca group was com-
pared with the >1000 mg/d Ca group. In our study, a 1000
mg/d increase in Ca was associated with a 10 % lowered
total CHOL:HDL-CHOL ratio; however, this relationship
was not signiﬁcant when adjusted for energy intake.
Furthermore, a higher Ca intake was correlated with reduced
concentrations of LDL-CHOL and total CHOL(7) as we
also observed. In agreement with the observational results,
Reid(69) reviewed the effect of a higher Ca intake on lipid pro-
ﬁle from intervention studies and concluded that higher Ca
intake reduced total CHOL and LDL-CHOL concentrations.
Furthermore, a few studies indicated an increase in
HDL-CHOL concentration(69) which we did not ﬁnd.
Several interventions(55–57) have found that a cheese diet
(+800 mg/d Ca) reduced concentrations of total CHOL by
Table 2. Description of faecal and urine samples (n 189)
(Medians with quartile 1 (Q1) and quartile 3 (Q3))
Median Q1, Q3
Faecal dry weight (g/d) 37·6 30·5, 48·7
Faecal wet weight (g/d) 148 113, 210
Faecal water content (%) 74·0 71·0, 77·0
Faecal energy excretion (kJ/d)* 800 630, 1044
Faecal fat excretion (g/d)* 7·68 5·65, 10·0
Faecal Ca excretion (mg/d)* 849 637, 1126
Urinary Ca excretion (mg/d)* 134 90·0, 203
Total Ca excretion (mg/d)† 1044 760, 1286
* n 186.
† n 183.
Table 3. Determinants of faecal fat excretion*
(β Values and 95 % confidence intervals)
Model II† (n 182) Model III‡ (n 182)
Log (fat % (%)) β 95 % CI P β 95 % CI P
Ca intake (Δ1 g/10 MJ per d) 0·12 0·04, 0·20 0·004 0·05 −0·02, 0·12 0·19
Age (Δ10 years) 0·01 −0·02, 0·04 0·67 −0·01 −0·03, 0·02 0·67
Sex
Women Ref. Ref.
Men −0·02 −0·08, 0·05 0·64 0·01 −0·04, 0·07 0·63
BMI (Δ5 kg/m2) −0·03 −0·06, 0·01 0·10 −0·01 −0·04, 0·03 0·74
Ca supplements
No Ref. Ref.
Yes 0·01 −0·07, 0·08 0·85 0·01 −0·06, 0·07 0·85
Dietary fibre (Δ5 g/10 MJ per d) – – – 0·06 0·04, 0·07 <0·001
Fat %, percentage fat excreted; Ref., reference value.
* All β values and 95 % confidence intervals in the table are raw data, i.e. data have not been back-transformed.
†Percentage fat excreted (fat %) (calculated as faecal fat excreted/fat intake × 100) was log-transformed and analysed by linear regression model adjusted for age, sex, BMI and
supplements containing Ca to investigate the effect of Ca intake (g/10 MJ per d).
‡Model II + additional adjustment for fibre intake. The interaction fibre × Ca was not significant (P = 0·95) and therefore removed from the model.
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0·21–0·26 mmol/l and LDL-CHOL by 0·20–0·22 mmol/l,
compared with a butter diet. In the present study, we found
an association of a 0·62 mmol/l reduction in total CHOL con-
centration per 1000 mg/10 MJ per d increase in Ca intake,
which is a larger predicted effect than that observed in other
studies(55–57). Furthermore, LDL-CHOL concentration was
associated with a 0·49 mmol/l reduction per 1000 mg/10
MJ per d increase in Ca intake and again a larger predicted
effect than observed in the intervention studies(55–57). In our
study, increased Ca intake did not increase HDL-CHOL con-
centration, and the reduced TAG concentration as well as the
reduced ratios of total CHOL:HDL-CHOL and LDL-CHOL:
HDL-CHOL disappeared when we adjusted for energy intake.
These latter observations add to the inconsistency in these
lipid markers where only a few studies(50,56) have found effects
of increasing Ca intake. In contrast, Zemel et al.(15) and
Jacobsen et al.(60) did not ﬁnd either long-term or short-term
periods on low v. high dairy consumption to affect lipid proﬁle
and Boon et al.(50) only found an effect on TAG concentration.
Many interventions are not directly comparable with our
study since they provided diets with a high fat(54) or high
SFA(48,49,58) content; thus the CHOL concentrations were
expected to increase during the intervention despite the higher
Ca intake. Increased Ca intake (800–1500 mg/d) reduced the
total CHOL and LDL-CHOL concentrations measured after
the intervention in the high Ca group, compared with the
low Ca groups(54,58). Comparable with our results, concentra-
tions of total CHOL differed by 0·29–0·48 mmol/l and
LDL-CHOL by 0·33–0·46 mmol/l(54,58). These effects have
also been observed by Ca-fortiﬁed products where a 1011
mg/d increase in Ca intake decreased total CHOL concentra-
tion by 0·24 mmol/l and tended to decrease LDL-CHOL con-
centration by 0·14 mmol/l(49). Furthermore, a 900 mg/d
increase in Ca resulted in a 0·33 mmol/l reduction in
LDL-CHOL concentration(48). The majority of studies inves-
tigating lipid proﬁle are in agreement with our results showing
that an increased Ca intake reduces total CHOL and
LDL-CHOL concentrations. However, some studies compar-
ing more than one intervention diet did not always ﬁnd a clear
dose–response pattern in the Ca effect within their
study(50,55,57,60) and we did not observe a clear dose–response
pattern when we grouped participants into tertiles based on
their Ca intake (data not shown). This could indicate that
there are unexplained effects related to the food matrix.
Table 4. Determinants of faecal energy excretion*
(β Values and 95 % confidence intervals)
Model II† (n 182) Model III‡ (n 181)
Square root (energy % (%)) β 95 % CI P β 95 % CI P
Ca intake (Δ1 g/10 MJ per d) 0·24 0·02, 0·46 0·031 0·07 −0·14, 0·28 0·50
Age (Δ10 years) 0·05 −0·04, 0·13 0·26 0·02 −0·06, 0·10 0·68
Sex
Women Ref. Ref.
Men −0·06 −0·23, 0·12 0·52 0·02 −0·14, 0·18 0·83
BMI (Δ5 kg/m2) −0·09 −0·18, 0·01 0·08 −0·03 −0·12, 0·06 0·57
Ca supplements
No Ref. Ref.
Yes 0·02 −0·18, 0·22 0·84 0·02 −0·17, 0·20 0·84
Dietary fibre (Δ5 g/10 MJ per d) – – – 0·14 0·10, 0·19 <0·001
Energy %, percentage energy excreted; Ref., reference value.
* All β values and 95 % confidence intervals in the table are raw data, i.e. data have not been back-transformed.
†Percentage energy excreted (energy %) (calculated as faecal energy excreted/total energy intake × 100) was square root-transformed and analysed by linear regression model
adjusted for age, sex, BMI and supplements containing Ca to investigate the effect of Ca intake (g/10 MJ per d).
‡Model II + additional adjustment for fibre intake. The interaction fibre × Ca was not significant (P = 0·99) and therefore removed from the model.
Table 5. Determinants of lipid profile
(β Values and 95 % confidence intervals)
Model II* Model II*
Total CHOL (mmol/l) (n 184) β 95 % CI P LDL-CHOL (mmol/l) (n 183) β 95 % CI P
Ca intake (Δ1 g/10 MJ per d) −0·62 −0·96,−0·28 <0·001 Ca intake (Δ1 g/10 MJ per d) −0·49 −0·78, −0·20 0·001
Age (Δ10 years) 0·36 0·22, 0·49 <0·001 Age (Δ10 years) 0·33 0·22, 0·45 <0·001
Sex Sex
Women Ref. Women Ref.
Men −0·31 −0·58, −0·04 0·027 Men 0·05 −0·19, 0·28 0·70
BMI (Δ5 kg/m2) 0·20 0·05, 0·34 0·011 BMI (Δ5 kg/m2) 0·19 0·06, 0·31 0·004
Ca supplements Ca supplements
No Ref. No Ref.
Yes 0·05 −0·27, 0·37 0·76 Yes 0·02 −0·25, 0·29 0·89
CHOL, cholesterol; Ref., reference value.
* Lipid outcome analysed by linear regression model adjusted for age, sex, BMI, supplements containing Ca and energy intake to investigate the effect of Ca intake (g/10 MJ per d).
Additional adjusting for interaction fibre × Ca was not significant (total CHOL P = 0·48, LDL-CHOL: P = 0·28) and therefore removed from the model. Neither had fibre intake a sig-
nificant influence on the models (total CHOL P = 0·14, LDL-CHOL P = 0·21) and model III for total CHOL and LDL-CHOL were therefore not different from model II.
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We observed an association of a 5·2 % reduction in systolic
BP per 1000 mg/10 MJ per d increase in Ca intake with no
relation to diastolic BP. This prediction is higher than ﬁndings
from two meta-analyses(70,71) that both found a smaller (0·9–
1·4 mmHg) effect on systolic BP.
In general, the predicted effects of Ca intake on blood
lipid proﬁle found in our free-living population are in agree-
ment with effects found in intervention studies; however, it
is important to consider the effect size. Elevated
LDL-CHOL concentration is associated with an increased
risk of CVD and a reduction of 1·0 mmol/l is estimated
to reduce all-cause mortality by 10 % and death related to
CVD by 20 %(41). This reduction of LDL-CHOL concen-
tration by entirely increasing Ca intake will in our study
require a 2 g/d increase in Ca intake, which does not
seem realistic when the habitual Ca intake for many
Danes is relatively high. However, increasing Ca intake
may be considered as a part of a preventive healthy diet
for those with a habitual low Ca intake.
The major limitation in this study is that the study popula-
tion does not necessarily reﬂect the general Danish population.
In Denmark, habitual Ca intake is high and to obtain associa-
tions over a large range in Ca intake, we aimed at recruiting
50 % of the participants with a Ca intake below 800 mg/d.
To obtain data from participants with a low Ca intake, we
included baseline data from participants in trial II that were
collected in the same time period and by the exact same meth-
ods as in trial I. The inclusion of data from ﬁfty extra partici-
pants broadens the Ca range, thus reducing the possibility of
making a type II error. Furthermore, we did not ﬁnd an asso-
ciation of Ca-containing supplements, which could be caused
by the fact that (1) too few of our participants consumed sup-
plements, (2) the effect of additional Ca from supplements
reached a Ca threshold or (3) the information obtained
about intake of Ca supplementation was too limited. In
total, thirty-three participants consumed Ca supplements in
the present study and excluding these participants from the
analyses did not alter the results.
The major strength of this study is that faeces and urine
samples were collected for 5 and 2 d, respectively. The median
(Q1, Q3) percentage of relative Ca excretion (urine and faecal
Ca excretion/Ca intake) was 94 (79, 115) %, indicating good
concordance between Ca measurements from the urine and
faecal samples and the diet registration. Additionally, we
included data that allowed us to investigate the association
of dietary ﬁbre, which may be a potential confounder of the
effect of Ca intake in relation to energy and fat excretion in
our population.
In conclusion, dietary Ca intake is negatively associated
with total CHOL and LDL-CHOL concentrations and sys-
tolic BP. Under free-living conditions, these associations do
not seem to be mediated by increased faecal excretion of
fat or energy.
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